|Bid||5.0100 x 4000|
|Ask||5.0200 x 1800|
|Day's Range||4.6427 - 4.8900|
|52 Week Range||2.4300 - 25.9500|
|Beta (5Y Monthly)||2.91|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.15|
Tilray announced preliminary results from a world-first clinical trial finding for chemotherapy induced nausea and vomiting.
There's often a lot of hype surrounding Robinhood stocks, and sometimes that can help carry share prices to astronomical heights. Tilray's stock is down 26% in September, and yet the company hasn't released any news since it reported its second-quarter results on Aug. 10. The Horizons Marijuana Life Sciences ETF (OTC: HMLSF) is down 13% this month, a more modest decline than Tilray's. What's surprising is that the British Columbia-based company is coming off a decent quarter during which it reported sales of $50.4 million for the period ending June 30.
John Kagia, New Frontier Data Cheif Knowledge Officer, joins Yahoo Finance's Zach Guzman to discuss the cannabis outlook amid COVID-19 and the 2020 Presidential election.